Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 6:50 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 769–792 of 21,991 matching trials from the live ClinicalTrials.gov search.

Filters: Recruiting Clear all

Conditions: Multiple Sclerosis (MS) - Relapsing-remitting
Interventions: Remibrutinib, Ocrelizumab (US); Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 40 Years to 70 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Caregiving for Cancer
Interventions: Psychosocial Intervention for Parental Caregivers of AYA with Cancer; Behavioral
Lead sponsor: Zeba Ahmad, Ph.D.; Other
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hodgkin Lymphoma
Interventions: Nivolumab, Doxorubicin Hydrochloride, Vinblastine, Dacarbazine; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 2 Years to 21 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Bronchopulmonary Dysplasia, Pulmonary Hypertension Due to Lung Diseases and Hypoxia, Extreme Prematurity, Ventilator Lung; Newborn, Ventilation Perfusion Mismatch
Interventions: Increase in the PEEP followed by decrease in the PEEP, Decrease in the PEEP followed by increase in the PEEP; Other
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 7 Days to 30 Days
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: PANS, PANDAS
Interventions: Not listed
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 3 Years to 17 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 2
States / cities: Lebanon, New Hampshire • Madison, Wisconsin

Conditions: Prostate Cancer, Adverse Effects Surgery, MRI, Ultrasound, Sexual Function Disturbances, Urinary Incontinence, Urinary Function Disorders, Prostate Biopsy, Ablation
Interventions: TRANBERG® Transperineal Fusion Laser--Induced Thermal Therapy of Prostate Cancer (TPF-LITT); Device
Lead sponsor: Urological Research Network, LLC; Other
Eligibility: 50 Years to 80 Years · Male only
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2033
U.S. locations: 1
States / cities: Hialeah, Florida

Conditions: Aging, Musculoskeletal Diseases, Osteoporosis
Interventions: 10 Weeks of Supervised Resistance Exercise Training, 10 Weeks of Supervised Endurance Exercise Training; Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 60 Years and older
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: B-Cell Non-Hodgkin Lymphoma, B-cell Acute Lymphoblastic Leukemia
Interventions: DuoCAR20.19.22-D95, Fludarabine (Conditional therapy), Cyclophosphamide (Conditional therapy); Drug
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2040
U.S. locations: 1
States / cities: Westwood, Kansas

Conditions: Locally Advanced / Metastatic Solid Tumors
Interventions: CR-001, Paclitaxel, trifluridine and tipiracil, Pemetrexed, Carboplatin, Oxaliplatin, Gemcitabin, Cisplatin, Capecitabine, FOLFOX; Drug
Lead sponsor: Crescent Biopharma, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 540 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 15
States / cities: Birmingham, Alabama • Los Angeles, California • Denver, Colorado + 12 more

Conditions: Parkinson's Disease, Sleep Fragmentation
Interventions: Deep Brain Stimulation; Device
Lead sponsor: University of Nebraska; Other
Eligibility: 18 Years to 80 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 2
States / cities: Omaha, Nebraska • Philadelphia, Pennsylvania

Conditions: Sensorineural Hearing Loss, Cochlear Implantation, Perceptual Adaptation
Interventions: Alternative Frequency Mapping; Other
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 1
States / cities: New York, New York

Conditions: Aneurysmal Subarachnoid Hemorrhage (aSAH), Headache
Interventions: Lidocaine (drug), Tx 360; Drug · Device
Lead sponsor: Wright State University; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Dayton, Ohio

Conditions: Multiple Sclerosis
Interventions: [18F] FZTA; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Major Depressive Disorder
Interventions: Zelquistinel; Drug
Lead sponsor: Syndeio Biosciences, Inc; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 164 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 34
States / cities: Birmingham, Alabama • Huntsville, Alabama • Encino, California + 30 more

Conditions: Sleep Disturbance, Inflammation, Psychosocial Functioning
Interventions: Mindfulness Meditation, Sleep Education; Behavioral
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years to 22 Years
Enrollment: 240 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Non-small Cell Lung Cancer Stage III
Interventions: Cemiplimab-Rwlc; Drug
Lead sponsor: Georgetown University; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 3
States / cities: Washington D.C., District of Columbia • St Louis, Missouri • Charlottesville, Virginia

Conditions: Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Head and Neck Carcinoma, Head and Neck Cancer Stage IV, Head and Neck Cancers - Throat
Interventions: Chemoradiation, Pamiparib, Hydroxyurea, Fluorouracil (5FU), Tislelizumab; Radiation · Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Migraine Disease, Patent Foramen Ovale
Interventions: Prasugrel 5mg, Transcatheter Closure of Patent Foramen Ovale; Drug · Device
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 55 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: New York, New York

Conditions: Systemic Lupus Erythematosus
Interventions: DZP, Placebo; Drug · Other
Lead sponsor: UCB Biopharma SRL; Industry
Eligibility: 16 Years and older
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 63
States / cities: Avondale, Arizona • Chandler, Arizona • Gilbert, Arizona + 55 more

Conditions: Repetitive Negative Thinking, Neurofeedback
Interventions: Mindfulness Training, Mindfulness-based Neurofeedback (Real mbNF), Sham mindfulness-based neurofeedback (Sham mbNF); Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 13 Years to 21 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Advanced Solid Tumor
Interventions: SGR-3515; Drug
Lead sponsor: Schrödinger, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 13
States / cities: New Haven, Connecticut • Chicago, Illinois • Ann Arbor, Michigan + 9 more

Conditions: Autism Spectrum Disorder
Interventions: Continuous Theta Burst Stimulation; Device
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: 11 Years to 25 Years
Enrollment: 106 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Autonomic Nerve Block
Interventions: Pecto-intercostal Fascial Block with 20 ml of 0.35% ropivacaine, Pecto-intercostal Fascial Block with normal saline; Procedure
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years and older
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Primary Care
Interventions: Behaviorally informed appointment communications, Control appointment communications; Behavioral
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years and older
Enrollment: 300,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Los Angeles, California

Search by objective public record fields.

Brain Imaging and Immune Changes During Remibrutinib Treatment in Multiple Sclerosis.

Adapting Psychosocial Resiliency Intervention for Parents of Adolescents and Young Adults With Cancer

Phase II Study Of Nivolumab Plus AVD In Pediatric, Adolescent, And Young Adult Patients With CHL

Ventilator Pressure and Optimization of Compliance and Hemodynamics

PEDI Pediatric Autoimmune Neuropsychiatric Disorder Associated With Streptococcus Study

TRANBERG® Transperineal MR/US Fusion Laser--Induced Thermal Therapy for Men With Prostate Cancer

Mode of Exercise and Bone Biomarkers in Older Veterans

Evaluating the Safety and Efficacy of DuoCAR20.19.22-D95 in Adult Patients With Relapsed or Refractory B-cell Malignancies

CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors

Adaptive Neurostimulation to Restore Sleep in Parkinson's Disease (Aim 2)

Perceptual Adaptation Following Cochlear Implantation (Aim 3a)

Intranasal Sphenopalatine Ganglion Blockade for Headaches Following Aneurysmal Subarachnoid Hemorrhage

This Study Involves a Positron Emission Tomography (PET) Scan Using a New Investigational Radioactive Tracer, [18F]-FZTA, to Detect Inflammation in the Brain. The Tracer Will be Tested in Healthy Younger Adults and Individuals With Multiple Sclerosis.

Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder

UCLA REST Study (REsearch on Sleep Techniques)

Neoadjuvant Chemo-Immunotherapy and Surgical Resection in Locally Advanced Non-small Cell Lung Cancer With N3 Lymph Node or Other High Risk Features

Dosing Study of Radiation Combined With Tislelizumab and Pamiparib in Patients With Previously Treated Head and Neck Cancer

Migraine Headaches Elimination With Patent Foramen Ovale-Directed Therapy

A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus

Effect of Mindfulness-based Neurofeedback for Adolescents With Elevated Repetitive Negative Thinking

Study of SGR-3515 In Participants With Advanced Solid Tumors.

Role of GABAergic Transmission in Auditory Processing in Autism Spectrum Disorder

Sternotomy PIFB Block in Open Heart Surgery

Arrival Time Implementation